Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene.
The overall goal of adoptive immunotherapy with genetically modified lymphocytes is to decrease the morbidity and mortality associated with allogeneic bone marrow transplantation. The initial data reviewed here suggest that the behavior of the allogeneic HStk transgenic cells can be modified after administration to patients. Further study is needed to identify the response rates and risks associated with this procedure. In particular, larger studies will be needed with appropriate randomization to determine if the response rate to genetically modified cells is equivalent to the response rates with unmodified cells. Wider application of these techniques in the initial setting of allogeneic transplantation will undoubtedly occur and such trials have been initiated at several institutions. Careful attention to vector, suicide gene, selectable marker, efficiency of transduction, and cell dose will be necessary when comparing different trials since these variables will probably affect transgenic cell survival and response rates. [figure: see text]
Link
C J
CJ
Human Gene Therapy Research Institute, Des Moines, IA 50309, USA.
Traynor
A
A
Seregina
T
T
Burt
R K
RK
D001804:Blood Transfusion, Autologous; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D015774:Ganciclovir / Q000627:therapeutic use*; D015316:Genetic Therapy; D020544:Graft vs Leukemia Effect; D006801:Humans; D016219:Immunotherapy, Adoptive; D007938:Leukemia / Q000628:therapy*; D017710:Lymphocyte Transfusion; D018139:Simplexvirus / Q000235:genetics*; D013937:Thymidine Kinase / Q000235:genetics*; D014184:Transplantation, Homologous
D013937:Thymidine Kinase; D015774:Ganciclovir